Is the HCV pipeline heading in the right direction?

Gastroenterology. 2013 Mar;144(3):482-5. doi: 10.1053/j.gastro.2013.01.018. Epub 2013 Jan 23.

Authors

Andrew Aronsohn¹, Andrew J Muir, Tracy Swan, Donald Jensen

Affiliation

¹ University of Chicago Medical Center, Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, Center for Liver Diseases, Chicago, Illinois, USA.

PMID: 23352458
DOI: 10.1053/j.gastro.2013.01.018

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use*
Coinfection / diagnosis
Coinfection / drug therapy
Drug Discovery / trends*
HIV Infections / complications
Health Services Accessibility
Hepatitis C / complications
Hepatitis C / drug therapy*
Humans
Liver Cirrhosis / drug therapy
Liver Cirrhosis / surgery
Liver Cirrhosis / virology
Liver Transplantation
Off-Label Use
Oligopeptides / therapeutic use
Proline / analogs & derivatives
Proline / therapeutic use
Treatment Outcome

Substances

Antiviral Agents
Oligopeptides
telaprevir
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Proline